Use of CAR-T cells for the treatment of relapsed and refractory multiple myeloma: a systematic review
A systematic review of published articles based on randomized clinical trials was conducted to ascertain the efficacy or perspective of using CAR-T cell therapy for refractory multiple myeloma. The PubMed database was searched with the combination of terms "multiple myeloma", "refract...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Oncologia Clínica, Sociedade Brasileira de Cirurgia Clínica and Sociedade Brasileira de Radioterapia
2024-01-01
|
| Series: | Brazilian Journal of Oncology |
| Subjects: | |
| Online Access: | https://www.brazilianjournalofoncology.com.br/details/272/en-US/uso-de-celulas-car-t-no-tratamento-de-mieloma-multiplo-recidivado-e-refratario--uma-revisao-sistematica |
| _version_ | 1797338608799055872 |
|---|---|
| author | Satchie Sakamoto Vanessa Sgnaolin |
| author_facet | Satchie Sakamoto Vanessa Sgnaolin |
| author_sort | Satchie Sakamoto |
| collection | DOAJ |
| description | A systematic review of published articles based on randomized clinical trials was conducted to ascertain the efficacy or perspective of using CAR-T cell therapy for refractory multiple myeloma. The PubMed database was searched with the combination of terms "multiple myeloma", "refractory multiple myeloma", "CAR T-cell", and the PRISMA criteria were followed. Of the 78 articles found, only 5 were selected. The studies used different treatment protocols and four different types of CAR-T cells. All studies obtained interesting results in terms of increased progression-free survival and negative minimal residual disease responses. Some authors detected an expansion of CAR-T cells and noted dose-dependent relationship between treatment effectiveness and serum BCMA levels. Although the results were promising, a small number of patients still relapsed a few months after CAR-T cell infusion. Therefore, this new line of therapy should be further investigated, as it significantly increases progression-free survival and improves quality of life. |
| first_indexed | 2024-03-08T09:33:45Z |
| format | Article |
| id | doaj.art-4b5701291b8b4e68b17bcf5b75431390 |
| institution | Directory Open Access Journal |
| issn | 2526-8732 |
| language | English |
| last_indexed | 2024-03-08T09:33:45Z |
| publishDate | 2024-01-01 |
| publisher | Sociedade Brasileira de Oncologia Clínica, Sociedade Brasileira de Cirurgia Clínica and Sociedade Brasileira de Radioterapia |
| record_format | Article |
| series | Brazilian Journal of Oncology |
| spelling | doaj.art-4b5701291b8b4e68b17bcf5b754313902024-01-30T14:18:08ZengSociedade Brasileira de Oncologia Clínica, Sociedade Brasileira de Cirurgia Clínica and Sociedade Brasileira de RadioterapiaBrazilian Journal of Oncology2526-87322024-01-012010.5935/2526-8732.20240443Use of CAR-T cells for the treatment of relapsed and refractory multiple myeloma: a systematic reviewSatchie Sakamoto0Vanessa Sgnaolin1PUCRS, Specialization Program in Pharmaceutical Oncology - Porto Alegre - RS - BrazilPUCRS, Graduate Program in Biomedical Gerontology - Porto Alegre - RS - BrazilA systematic review of published articles based on randomized clinical trials was conducted to ascertain the efficacy or perspective of using CAR-T cell therapy for refractory multiple myeloma. The PubMed database was searched with the combination of terms "multiple myeloma", "refractory multiple myeloma", "CAR T-cell", and the PRISMA criteria were followed. Of the 78 articles found, only 5 were selected. The studies used different treatment protocols and four different types of CAR-T cells. All studies obtained interesting results in terms of increased progression-free survival and negative minimal residual disease responses. Some authors detected an expansion of CAR-T cells and noted dose-dependent relationship between treatment effectiveness and serum BCMA levels. Although the results were promising, a small number of patients still relapsed a few months after CAR-T cell infusion. Therefore, this new line of therapy should be further investigated, as it significantly increases progression-free survival and improves quality of life.https://www.brazilianjournalofoncology.com.br/details/272/en-US/uso-de-celulas-car-t-no-tratamento-de-mieloma-multiplo-recidivado-e-refratario--uma-revisao-sistematicamultiple myelomaimmunotherapy, adoptiveb-cell maturation antigenrecurrence |
| spellingShingle | Satchie Sakamoto Vanessa Sgnaolin Use of CAR-T cells for the treatment of relapsed and refractory multiple myeloma: a systematic review Brazilian Journal of Oncology multiple myeloma immunotherapy, adoptive b-cell maturation antigen recurrence |
| title | Use of CAR-T cells for the treatment of relapsed and refractory multiple myeloma: a systematic review |
| title_full | Use of CAR-T cells for the treatment of relapsed and refractory multiple myeloma: a systematic review |
| title_fullStr | Use of CAR-T cells for the treatment of relapsed and refractory multiple myeloma: a systematic review |
| title_full_unstemmed | Use of CAR-T cells for the treatment of relapsed and refractory multiple myeloma: a systematic review |
| title_short | Use of CAR-T cells for the treatment of relapsed and refractory multiple myeloma: a systematic review |
| title_sort | use of car t cells for the treatment of relapsed and refractory multiple myeloma a systematic review |
| topic | multiple myeloma immunotherapy, adoptive b-cell maturation antigen recurrence |
| url | https://www.brazilianjournalofoncology.com.br/details/272/en-US/uso-de-celulas-car-t-no-tratamento-de-mieloma-multiplo-recidivado-e-refratario--uma-revisao-sistematica |
| work_keys_str_mv | AT satchiesakamoto useofcartcellsforthetreatmentofrelapsedandrefractorymultiplemyelomaasystematicreview AT vanessasgnaolin useofcartcellsforthetreatmentofrelapsedandrefractorymultiplemyelomaasystematicreview |